|Other Names||Zinc phosphodiesterase ELAC protein 2, ElaC homolog protein 2, Heredity prostate cancer protein 2, Ribonuclease Z 2, RNase Z 2, tRNA 3 endonuclease 2, tRNase Z 2, ELAC2, HPC2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Zinc phosphodiesterase, which displays mitochondrial tRNA 3'-processing endonuclease activity. Involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA.|
|Cellular Location||Mitochondrion. Nucleus. Note=Mainly mitochondrial|
|Tissue Location||Widely expressed. Highly expressed in heart, placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. Weakly expressed in brain, lung, spleen, thymus, prostate, small intestine, colon and leukocytes|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ELAC2 has a C-terminal domain with tRNA; processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest.
Beuten, J., et al. Cancer Epidemiol. Biomarkers Prev. 19(2):588-599(2010)Elbarbary, R.A., et al. FEBS Lett. 583(19):3241-3246(2009)Sugiyama, N., et al. Mol. Cell Proteomics 6(6):1103-1109(2007)Noda, D., et al. Oncogene 25(41):5591-5600(2006)Takaku, H., et al. Nucleic Acids Res. 31(9):2272-2278(2003)
If you have any additional inquiries please email technical services at email@example.com.